Detailed Information

Cited 36 time in webofscience Cited 36 time in scopus
Metadata Downloads

Change in Serum Hepatitis B Surface Antigen Level and Its Clinical Significance in Treatment-naive, Hepatitis B e Antigen-positive Patients Receiving Entecavir

Authors
Jung, Young KulKim, Ji HoonLee, Young SunLee, Hyun JungYoon, EileenJung, Eun SukHong, Seung KwonJoo, Moon KyungYeon, Jong EunPark, Jong JaeKim, Jae SeonBak, Young-TaeByun, Kwan Soo
Issue Date
Oct-2010
Publisher
Lippincott Williams & Wilkins Ltd.
Keywords
hepatitis B surface antigen; chronic hepatitis B; treatment-naive; hepatitis B e antigen positive; entecavir
Citation
Journal of Clinical Gastroenterology, v.44, no.9, pp 653 - 657
Pages
5
Indexed
SCI
SCIE
SCOPUS
Journal Title
Journal of Clinical Gastroenterology
Volume
44
Number
9
Start Page
653
End Page
657
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/14447
DOI
10.1097/MCG.0b013e3181d52946
ISSN
0192-0790
1539-2031
Abstract
Background/Aim We investigated changes in hepatitis B surface antigen (HBsAg) level and its correlation with clinical outcomes in treatment-naive chronic hepatitis B (CHB) patients undergoing entecavir therapy. Patients and Methods Among 51 hepatitis B e antigen (HBeAg)-positive treatment-naive CHB patients receiving entecavir for more than 1 year, 28 were enrolled. HBsAg levels were measured at baseline, 6 months, and 12 months after treatment using the Architect HBsAg QT assay (Abbott, dynamic; range: 0.05 to 125,000 IU/mL). Serum alanine aminotransferase, HBeAg, anti-HBe, and hepatitis B virus (HBV) DNA (Cobas Taqman: low detection limit 1.84 log10 copies/mL) were measured at baseline and every 3 months. The HBsAg response was defined as an HBsAg level that decreased more than 1 log10 IU/mL from baseline level at 12 months after entecavir treatment. Results Twenty-eight patients were treated for a median period of 21 months (range: 18 to 24 mo). Serum HBsAg level showed a mean of 4.0, 3.7, and 3.6 log10 IU/mL at pretreatment, 6, and 12 months, respectively, and declined significantly (P<0.001). Serum HBV DNA level showed a mean of 8.1, 3.1, and 2.4 log10 copies/mL at pretreatment, 6, and 12 months, respectively, and declined significantly (P<0.001). The decline in HBsAg level was significantly correlated with that of the HBV DNA level at 12 months from baseline (γ=0.391, P=0.044). Five patients showed an HBsAg response, and cumulative incidence of HBeAg loss at 1 year after entecavir treatment was 80% versus 30% in patients with an HBsAg response and those without, respectively (P=0.034). Conclusions Monitoring changes in quantitative HBsAg level could be a useful parameter for assessing the response to entecavir therapy in HBeAg-positive treatment-naive CHB patients.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Ji Hoon photo

Kim, Ji Hoon
Guro Hospital (Department of Gastroenterology and Hepatology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE